Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
| ▸ | DRD4 | P21917 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | CRHBP | P24387 | 1/20 | 0.48 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11303 | 0.92 | KCNH2 (0.52) | DRD2DRD4DRD3HRH3KCNH2 | |
| SCHEMBL9570575 | 0.84 | DRD2 (0.65) | DRD2DRD4DRD3HRH3KCNH2 | |
| SCHEMBL9969479 | 0.83 | DRD2 (0.54) | DRD2DRD4DRD3HRH3KCNH2 | |
| SCHEMBL9570561 | 0.82 | HRH3 (0.69) | DRD2DRD4DRD3HRH3KCNH2 | |
| SCHEMBL10558691 | 0.82 | HRH3 (0.69) | DRD2DRD4DRD3HRH3KCNH2 | |
| SCHEMBL10559291 | 0.82 | HRH3 (0.69) | DRD2DRD4DRD3HRH3KCNH2 | |
| SCHEMBL10556391 | 0.82 | HRH3 (0.69) | DRD2DRD4DRD3HRH3KCNH2 | |
| SCHEMBL5390369 | 0.82 | HRH3 (0.69) | DRD2DRD4DRD3HRH3KCNH2 | |
| SCHEMBL10554981 | 0.82 | HRH3 (0.69) | DRD2DRD4DRD3HRH3KCNH2 | |
| SCHEMBL9570637 | 0.82 | HRH3 (0.69) | DRD2DRD4DRD3HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2382218-A1 | DELTA-5-DESATURASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2011-11-02 | — | — | EP | disclosed |
| WO-2010087467-A1 | DELTA-5-DESATURASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-05 | — | — | WO | disclosed |
| US-20100190747-A1 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190747-A1 | Fused ring compound and use thereof | CYP46A1, LTB4R2, PTGES | DRD2 4328/4885DRD4 4119/4885DRD3 3531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.